1. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. Issue 11 (November 2020) Authors: Prat, Aleix; Guarneri, Valentina; Paré, Laia; Griguolo, Gaia; Pascual, Tomás; Dieci, Maria V; Chic, Núria; González-Farré, Blanca; Frassoldati, Antonio; Sanfeliu, Esther; Cejalvo, Juan M; Muñoz, Montserrat; Bisagni, Giancarlo; Brasó-Maristany, Fara; Urso, Loredana; Vidal, Maria; Brandes, Alba A; ... Journal: Lancet oncology Issue: Volume 21:Issue 11(2020) Page Start: 1455 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Pilot, Phase II, Randomized, Open‐Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab‐Paclitaxel to That of Solvent‐Based Paclitaxel as the First‐Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2‐Negative Metastatic Breast Cancer. (25th April 2019) Authors: Ciruelos, Eva; Apellániz‐Ruiz, María; Cantos, Blanca; Martinez‐Jáñez, Noelia; Bueno‐Muiño, Coralia; Echarri, Maria‐Jose; Enrech, Santos; Guerra, Juan‐Antonio; Manso, Luis; Pascual, Tomas; Dominguez, Cristina; Gonzalo, Juan‐Francisco; Sanz, Juan‐Luis; Rodriguez‐Antona, Cristina; Sepúlveda, Juan‐Ma... Journal: Oncologist Issue: Volume 24:Number 11(2019) Page Start: e1024 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis. (March 2022) Authors: Villacampa, Guillermo; Tolosa, Pablo; Salvador, Fernando; Sánchez-Bayona, Rodrigo; Villanueva, Lorea; Dienstmann, Rodrigo; Ciruelos, Eva; Pascual, Tomas Journal: Cancer treatment reviews Issue: Volume 104(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Issue 16 (December 2015) Authors: Cortés, Javier; Dieras, Véronique; Ro, Jungsil; Barriere, Jérôme; Bachelot, Thomas; Hurvitz, Sara; Le Rhun, Emilie; Espié, Marc; Kim, Sung-Bae; Schneeweiss, Andreas; Sohn, Joo Hyuk; Nabholtz, Jean-Marc; Kellokumpu-Lehtinen, Pirkko-Liisa; Taguchi, Julie; Piacentini, Federico; Ciruelos, Eva; Bono, ... Journal: Lancet oncology Issue: Volume 16:Issue 16(2015) Page Start: 1700 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Issue 4 (April 2021) Authors: Rugo, Hope S; Lerebours, Florence; Ciruelos, Eva; Drullinsky, Pamela; Ruiz-Borrego, Manuel; Neven, Patrick; Park, Yeon Hee; Prat, Aleix; Bachelot, Thomas; Juric, Dejan; Turner, Nicholas; Sophos, Nickolas; Zarate, Juan Pablo; Arce, Christina; Shen, Yu-Ming; Turner, Stuart; Kanakamedala, Hemanth; H... Journal: Lancet oncology Issue: Volume 22:Issue 4(2021) Page Start: 489 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. Issue 6 (June 2018) Authors: Pernas, Sonia; Martin, Miguel; Kaufman, Peter A; Gil-Martin, Marta; Gomez Pardo, Patricia; Lopez-Tarruella, Sara; Manso, Luis; Ciruelos, Eva; Perez-Fidalgo, Jose Alejandro; Hernando, Cristina; Ademuyiwa, Foluso O; Weilbaecher, Katherine; Mayer, Ingrid; Pluard, Timothy J; Martinez Garcia, Maria; V... Journal: Lancet oncology Issue: Volume 19:Issue 6(2018) Page Start: 812 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists. (1st January 2019) Authors: Sánchez-Rovira, Pedro; Zamora, Pilar; Salvador-Bofill, Javier; Morales, Serafín; Martínez-Jáñez, Noelia; Martínez-de-Dueñas, Eduardo; Lluch, Ana; Illarramendi, José Juan; Gómez-Pardo, Patricia; Gavilá Gregori, Joaquín; García-Palomo, Andrés; García-Mata, Jesús; Fernández, Yolanda; del Barco, Soni... Journal: Journal of drug assessment Issue: Volume 8(2019)Supplement 1 Page Start: 62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 1 (January 2018) Authors: Di Leo, Angelo; Johnston, Stephen; Lee, Keun Seok; Ciruelos, Eva; Lønning, Per E; Janni, Wolfgang; O'Regan, Ruth; Mouret-Reynier, Marie-Ange; Kalev, Dimitar; Egle, Daniel; Csőszi, Tibor; Bordonaro, Roberto; Decker, Thomas; Tjan-Heijnen, Vivianne C G; Blau, Sibel; Schirone, Alessio; Weber, Denis; ... Journal: Lancet oncology Issue: Volume 19:Issue 1(2018) Page Start: 87 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. CLRM-14. OPEN-LABEL, MULTINATIONAL, MULTICENTER, PHASE 3B/4 STUDY OF TRASTUZUMAB DERUXTECAN (T-DXD) IN PATIENTS WITH OR WITHOUT BASELINE BRAIN METASTASIS (BM) WITH PREVIOUSLY TREATED ADVANCED/METASTATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE BREAST CANCER (HER2+ BC): DESTINY-BREAST12. (21st September 2021) Authors: Lin, Nancy U; Ciruelos, Eva; Jerusalem, Guy; Müller, Volkmar; Niikura, Naoki; Viale, Giuseppe; Oscroft, Emma; Anand, Shawn; Walker, Graham; Harbeck, Nadia Journal: Neuro-oncology advances Issue: Volume 3(2021)Supplement 4 Page Start: iv4 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients. (February 2020) Authors: Cortés, Javier; Ciruelos, Eva; Pérez-García, José; Albanell, Joan; García-Estévez, Laura; Ruiz–Borrego, Manuel; Espinosa, Ruth; Gallegos, Isabel; González, Santiago; Álvarez, Isabel; Llombart, Antonio Journal: Cancer treatment reviews Issue: Volume 83(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗